Envafolimab Combined With Chemotherapy in Neoadjuvant and Conversion Therapy for Head and Neck Squamous Cell Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 25, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Efficacy and Safety
Interventions
DRUG

Envafolimab combined with chemotherapy

envafolimab: 150 mg once every 1 week for 8 doses subcutaneously on day 1 Chemotherapy: nab-paclitaxel + cisplatin/carboplatin 3 cycles; Albumin paclitaxel 260 mg/m2, cisplatin 75 mg/m2 divided into 3 days, carboplatin AUC 5 applied on the first day.

All Listed Sponsors
lead

Hairong Liu

OTHER